Pharmaceuticals & Therapeutics

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

With a new CEO, a leaner budget, and crucial data on the horizon for its brain and obesity drugs, Neumora is navigating a pivotal phase of growth.

Bonerge is betting that cellular recovery is the key to mitigating the high cost of night shift work. Its real-world trial could redefine human capital investment.

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

Journey Medical posts a stellar 23% revenue jump, nearing profitability. But beyond the headlines, a crucial SEC filing reveals a complex financial reality.

A Chinese firm's historic USFDA approval for a complex generic drug ingredient signals a major shift in the global pharma supply chain and promises cheaper medicines.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

A new composition of matter patent extends protection for Alterity's lead drug to 2045, de-risking its path in MSA and opening a new front against Parkinson's.

A new partnership aims to bring the first FDA-approved, oral ketamine pill for depression to your home, using AI and real-world data to ensure safety.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

With a massive Series B and the launch of a Phase 3 study, Vaderis Therapeutics is poised to deliver the first-ever approved therapy for a long-neglected rare disease.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.